Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab
January 06, 2023 14:25 ET | Global Alzheimer's Platform Foundation
Washington, D.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- "We applaud the Food and Drug Administration (FDA)’s decision to grant accelerated approval to lecanemab, a treatment that offers millions of...
First of its Kind Head-to-Head Study Comparing Leading Biomarkers for Detecting Alzheimer’s Disease Closes With Unprecedented Representation from Underrepresented Populations
November 15, 2022 06:00 ET | Global Alzheimer's Platform Foundation
WASHINGTON, DC, Nov. 15, 2022 (GLOBE NEWSWIRE) -- In 18 months, the Global Alzheimer’s Platform Foundation (GAP) recruited more than 1,000 participants to enroll in the first-ever head-to-head study...
Global Alzheimer’s Platform Foundation (GAP) Celebrates Lecanemab’s Positive Clinical Trial Results
September 28, 2022 12:09 ET | Global Alzheimer's Platform Foundation
WASHINGTON, DC, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and welcomes the Phase 3 study results on lecanemab for treating Alzheimer’s...
Global Alzheimer’s Platform Foundation and WCG collaborate to improve access to clinical trials for traditionally underrepresented communities
August 01, 2022 08:00 ET | Global Alzheimer's Platform Foundation
WASHINGTON, DC, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) and WCG announced a joint program today that will increase the availability of educational...
GAP Takes Alzheimer’s Clinical Trials On the Road to Remove Barriers to Access
July 14, 2022 14:36 ET | Global Alzheimer's Platform Foundation
WASHINGTON, DC, July 14, 2022 (GLOBE NEWSWIRE) -- Today, Global Alzheimer's Platform Foundation (GAP) President John Dwyer announced the launch of a new mobile health site, which is hitting the road...